|Videos|March 15, 2022
Decentralized Clinical Trials in a Covid-19 Landscape
Author(s)YPrime
YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.
• Regulatory has begun to investigate new methods and technologies for the clinical trial process.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.
Related Content
Trending on Applied Clinical Trials Online
1
AI-Enabled Sites and the Future of Trial Planning: Q&A with Liz Beatty, Inato
2
ACT Brief: CTTI Risk Myth-Busting, Hidden ePRO Exclusion Criteria, and Patient-Centered Care Models
3
Operational Pragmatism in ePRO-heavy trials
4
Could Selective Safety Data Collection Become the Industry's New Default?
5